Patent Claims For Fibromyalgia Treatment Method Were Not Obvious, PTAB Panel Says
WASHINGTON, D.C. — A patent examiner erred in rejecting as obvious a patent application for a fibromyalgia treatment that uses an antihistamine because the examiner failed to show that the referenced...To view the full article, register now.
Already a subscriber? Click here to view full article